Showing 42,401 - 42,420 results of 113,932 for search '(( 5 ((mean decrease) OR (a decrease)) ) OR ( a ((fold decrease) OR (point decrease)) ))', query time: 1.26s Refine Results
  1. 42401

    Flow diagram. by Katja Linde (4169875)

    Published 2024
    “…Future studies should include additional assessment points in the first trimester and more than six months postpartum and try to include a matched control group of non-pregnant women to compare prevalence rates and trajectory of body image dissatisfaction.…”
  2. 42402

    The lagged impact of different factors and scenarios on COVID-19 transmission during the Delta wave in 2021. by Eimear Cleary (6794792)

    Published 2025
    “…<b>(G)</b> – (<b>I</b>) COVID-19 lag-response association for precipitation (Prec) at 0.05, 0.5, and 1m, relative to the overall mean of 0.15m. …”
  3. 42403
  4. 42404
  5. 42405
  6. 42406

    A Novel Potent Anticancer Compound Optimized from a Natural Oridonin Scaffold Induces Apoptosis and Cell Cycle Arrest through the Mitochondrial Pathway by Shengtao Xu (513564)

    Published 2017
    “…Furthermore, <b>13p</b> induced apoptosis and cell cycle arrest at the G2/M phase. A decrease in mitochondrial membrane potential and an increase in Bax/Bcl-2 ratio, accompanied by activated caspase-3 cleavage, were observed in MCF-7 cells after treatment with <b>13p</b>, suggesting that the mitochondrial pathway was involved in the <b>13p</b>-mediated apoptosis. …”
  7. 42407
  8. 42408
  9. 42409
  10. 42410
  11. 42411
  12. 42412
  13. 42413
  14. 42414

    Preparation and NMR Spectra of the (Trifluoromethyl)argentates(III) [Ag(CF<sub>3</sub>)<i><sub>n</sub></i>X<sub>4-<i>n</i></sub><i></i>]<sup>-</sup>, with X = CN (<i>n</i> = 1−3),... by Reint Eujen (2973468)

    Published 1997
    “…In the [Ag(CF<sub>3</sub>)<sub>3</sub>(CH<sub>3</sub>)]<sup>-</sup> anion, the Ag−CH<sub>3</sub> distance (2.097(5) Å) is slightly shorter than the average Ag−CF<sub>3</sub> bond lengths (2.119(10) Å).…”
  15. 42415

    Attaining the Utmost Stability and Energy of Carbonyl Azides by the Synergistic Improvement of Conjugation and H-bonding by Baojing Tian (19941820)

    Published 2024
    “…In this study, we present a new family of carbonyl azides, 5-nitro-1H-1,2,4-triazol-3-yl-carbamoyl-azide (NTCA), which was synthesized through in situ oxidation cleavage of amino-tetrazole. …”
  16. 42416
  17. 42417

    Synthetic Control of Excited-State Properties in Cyclometalated Ir(III) Complexes Using Ancillary Ligands by Jian Li (41607)

    Published 2005
    “…The Ir−C<sub>aryl</sub> bond lengths in (<i>tpy</i>)<sub>2</sub>Ir(CN-<i>t-</i>Bu)<sub>2</sub><sup>+</sup> (2.047(5) and 2.072(5) Å) and (<i>tpy</i>)<sub>2</sub>Ir(PPh<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>BPh<sub>2</sub> (2.047(9) and 2.057(9) Å) are longer than their counterparts in (<i>tpy</i>)<sub>2</sub>Ir(acac) (1.982(6) and 1.985(7) Å). …”
  18. 42418

    Synthetic Control of Excited-State Properties in Cyclometalated Ir(III) Complexes Using Ancillary Ligands by Jian Li (41607)

    Published 2005
    “…The Ir−C<sub>aryl</sub> bond lengths in (<i>tpy</i>)<sub>2</sub>Ir(CN-<i>t-</i>Bu)<sub>2</sub><sup>+</sup> (2.047(5) and 2.072(5) Å) and (<i>tpy</i>)<sub>2</sub>Ir(PPh<sub>2</sub>CH<sub>2</sub>)<sub>2</sub>BPh<sub>2</sub> (2.047(9) and 2.057(9) Å) are longer than their counterparts in (<i>tpy</i>)<sub>2</sub>Ir(acac) (1.982(6) and 1.985(7) Å). …”
  19. 42419

    Quality as a function of coverage, according to theoretical model. by Melissa J. Hubisz (51880)

    Published 2011
    “…The solid black curve shows that expected sequence quality increases nearly linearly with expected coverage, at a rate of ∼3.62 <i>phred</i> units per additional 1× of coverage, corresponding to a 10−3.62/lO≈43% decrease in the error rate. …”
  20. 42420

    The difference in outcome parameters between groups. by Mi-yeon Yu (813778)

    Published 2017
    “…<p>Outcome parameters represent the followings; O1, decrease of time-averaged proteinuria from trial phase and to the observational phase; O2, remission of UPCR <0.2 g/g cr during observational phase; O3, rapid decline of eGFR ≥5 mL/min/1.73 m<sup>2</sup> during observational phase; O4, composite outcome of increase in serum cr level (≥50% from baseline) noted during observational phase or deterioration of renal function to end stage renal disease. …”